# A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

> **NCT03819049** · PHASE1,PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 836 (actual)

## Conditions studied

- Extraintestinal Pathogenic Escherichia Coli Prevention

## Interventions

- **BIOLOGICAL:** ExPEC10V
- **BIOLOGICAL:** ExPEC4V
- **BIOLOGICAL:** Prevnar 13
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03819049
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-06
- **Primary completion:** 2021-06-08
- **Final completion:** 2024-12-18
- **Target enrollment:** 836 (ACTUAL)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03819049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03819049, "A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT03819049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*